These days, we all have been hearing about a new vaccine coming into the Indian markets. This vaccine is ZyCov-D and is the first plasmid DNA vaccine to come into existence. With the development of this vaccine, a new benchmark has been set. Along with this comes various questions that the public wants to know about. Therefore, to help you know more about the vaccine, we have mentioned ZyCov-D Vaccine below. What is Zycov-D Efficacy, Zycov-D Dosage Information, Do ZyCov-D Got Approval From WHO.
Navigate To Content
ZyCov-D Vaccine Efficacy, Dosage
Zydus Cadila, a company based in Ahmedabad, Gujarat has developed ZyCov-D and has also applied for its emergency use. The officials have applied to Central Drugs Standard Control Organization (CDSCO) for the decision on emergency usage. With this development, the vaccine becomes the world’s first DNA-based vaccine against Covid-19. ZyCov-D is a non-replicating and genetically engineered type of DNA molecule, which we know as a plasmid. In the case of SARS-CoV-2, the developers code the plasmids with instructions to create the spike protein of the virus. On receiving the vaccine, a recipient’s body receives the code to begin creating the outer layer (spiky) of the virus. Then, one’s immune system recognizes this as a threat and develops antibodies against it. Therefore, provides great security against the virus to the recipient.
How Effective and Safe is the ZyCov-D Vaccine ?
Today, we have a lot of vaccines in the market. India started with Covishield and Covaxin. Today, the authorities have also approved Sputnik V and Moderna for emergency uses. Now, pregnant women are also eligible to take the vaccines. Thus, the need for vaccines has increased further. Amidst this, the development of ZyCov-D comes as a great success. As we know, the vaccines we have been using so far had to be given in two doses. However, the developers of ZyCov-D have said that the vaccine will be given in three doses with a gap of 28 days in between two doses. Other than this, the vaccine won’t be given through injections. Instead, the spring-powered device will deliver the vaccine as a narrow and precise stream. Zydus Cadila has developed with support from the Indian Council of Medical Research and the Department of Biotechnology.
The authorities have tested the vaccine in three trials with over 28,000 participants. Among these, 1000 participants were of the age group 12 to 18 years. In the first two trials, the authorities found that the vaccine is ‘Safe and Immunogenic’. As per the reports on the trials, the vaccine brought symptomatic cases down by nearly 67% in comparison to those who didn’t receive the vaccine. This claim came after RT-PCR test reports of 79-90 virus cases of people vaccinated in the third phase trials. Zydus Cadila has also said that getting two doses of the vaccine is enough to prevent severe symptoms and death. However, complete three doses help in keeping moderate symptoms away.
ZyCov-D Against Delta Variant Efficacy
During the peak of the second wave, the officials conducted the third trial of ZyCov-D at 50 trail sites. The vaccine showed positive results and that’s why the company believes that the vaccine is very effective against the Delta Plus Variant. We know that out of all the strains found, 99% were of the Delta Variant in the surveillance test, thus, the reports of the vaccine are from the peak second wave season. Dr. Patel of Zydus Cadila has said that if needed, the company can upgrade the vaccine to target any other variants. The company is ready to deal with more virulent and infectious variants if the need arises in the future.
The company has so far submitted Phase 1 trial data and is now preparing for the publication of Phase 2 trial data. However, the Phase 3 data will take four to six months to get published for peer review. Talking about historical evidence, the DNA vaccine shave shown some safety concerns regarding conversion to cellular DNA and auto-immune diseases. But, Dr. Patel from Zydus Cadila has called the vaccine non-infectious, as it doesn’t contain particles like viral vectors. These viral vectors become responsible for minimizing the risks of vaccine-enhanced diseases.
Needle Free Vaccine ZyCov-D
Right now, the company has given an application to the regulatory authorities for the vaccine’s emergency use. Once the initial process is complete, the Subject Expert Committee of CDSCO will be reached. Then, the company will have to present the data in a meeting. After the meeting, the SEC will decide if the emergency use of the vaccine should be recommended. Even though there are sufficient shreds of evidence on the efficiency of the vaccine in teenagers, the authorities will come to the final conclusion.
If the regulatory authorities clear the trials and accept the vaccine for emergency uses, the company will manufacture around 120 million doses every year. Thus, around 40 million people will vaccinate with three doses in a year. Therefore, from August onwards, the company will begin producing 10 million doses each month and by December, there will be 50 million doses for public use.
Links For ZyCov-D Vaccine Dosage, Efficacy
ZyCov-D Vaccine and All Related Details FAQs
The developers of the vaccine have claimed that the vaccine has been tested in the peak wave time and thus, is effective to fight against the Delta variant.
The recipients will receive the vaccine in total three doses with 28 days gap in between every two doses.
Yes, the company has tested the vaccine on teenagers where around 1000 participants were in the age group 12 years to 18 years.